Statements of Stockholders’ Equity (Deficit) - USD ($)	Common Stock CS – Shares CS – Par	Preferred Stock Shares Par Amount	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2023	$ 5,340	$ 1,302	$ 5,495,330	$ (29,518,187)	$ (24,016,215)
Balance (in Shares) at Dec. 31, 2023	5,340,000	1,302,082
Conversion of Preferred Stock to Common Stock	$ 651	$ (1,302)	651
Conversion of Preferred Stock to Common Stock (in Shares)	651,041	(1,302,082)
Preferred Dividends				(31,250)	(31,250)
Net Loss				(1,458,992)	(1,458,992)
Balance at Mar. 31, 2024	$ 5,991		5,495,981	(31,008,429)	(25,506,457)
Balance (in Shares) at Mar. 31, 2024	5,991,041
Balance at Dec. 31, 2023	$ 5,340	$ 1,302	5,495,330	(29,518,187)	(24,016,215)
Balance (in Shares) at Dec. 31, 2023	5,340,000	1,302,082
Stock-based compensation
Net Loss					(3,016,472)
Balance at Jun. 30, 2024	$ 5,991		5,495,981	(32,565,909)	(27,063,937)
Balance (in Shares) at Jun. 30, 2024	5,991,041
Balance at Dec. 31, 2023	$ 5,340	$ 1,302	5,495,330	(29,518,187)	(24,016,215)
Balance (in Shares) at Dec. 31, 2023	5,340,000	1,302,082
Balance at Dec. 31, 2024	$ 20,870		35,144,967	(38,432,375)	$ (3,266,538)
Balance (in Shares) at Dec. 31, 2024	20,869,908				20,869,908
Balance at Mar. 31, 2024	$ 5,991		5,495,981	(31,008,429)	$ (25,506,457)
Balance (in Shares) at Mar. 31, 2024	5,991,041
Net Loss				(1,557,480)	(1,557,480)
Balance at Jun. 30, 2024	$ 5,991		5,495,981	(32,565,909)	(27,063,937)
Balance (in Shares) at Jun. 30, 2024	5,991,041
Balance at Dec. 31, 2024	$ 20,870		35,144,967	(38,432,375)	$ (3,266,538)
Balance (in Shares) at Dec. 31, 2024	20,869,908				20,869,908
APIC Warrants Patent License					$ 330,781
Commitment shares issued for Equity Line of Credit	$ 157		568,078		568,235
Commitment shares issued for Equity Line of Credit (in Shares)	157,407
Common Stock Shares issued for Services	$ 321		1,446,980		$ 1,447,301
Common Stock Shares issued for Services (in Shares)	320,000				20,000
Stock-based compensation			941,283		$ 941,283
Net Loss				(3,876,859)	(3,876,859)
Balance at Mar. 31, 2025	$ 21,348		38,101,308	(42,309,234)	(4,186,578)
Balance (in Shares) at Mar. 31, 2025	21,347,315
Balance at Dec. 31, 2024	$ 20,870		35,144,967	(38,432,375)	$ (3,266,538)
Balance (in Shares) at Dec. 31, 2024	20,869,908				20,869,908
Conversion of Warrants to Common Stock (in Shares)					3.571429
Conversion of Preferred Stock to Common Stock (in Shares)	3,962,129
Stock-based compensation					$ 1,846,465
Net Loss					(8,413,481)
Balance at Jun. 30, 2025	$ 29,665		51,759,838	(46,845,856)	$ 4,943,647
Balance (in Shares) at Jun. 30, 2025	29,664,916				29,664,916
Balance at Mar. 31, 2025	$ 21,348		38,101,308	(42,309,234)	$ (4,186,578)
Balance (in Shares) at Mar. 31, 2025	21,347,315
Conversion of Preferred Shares Mezzanine Equity to Common Stock	$ 3,962		2,988,070		2,992,032
Conversion of Preferred Shares Mezzanine Equity to Common Stock (in Shares)	3,962,129
Issuance Common Stock for Patent Purchase	$ 2,164		2,897,884		2,900,048
Issuance Common Stock for Patent Purchase (in Shares)	2,164,215
Conversion of Warrants to Common Stock	$ 2,181		2,481,284		2,483,465
Conversion of Warrants to Common Stock (in Shares)	2,181,257
APIC Warrants Liability Reclass Preferred Stock			878,153		878,153
Pending Issuance of Common Stock to Ayala #444,041			595,016		595,016
APIC Warrants Patent License			2,902,951		2,902,951
Common Stock Shares issued for Services	$ 10		9,990		10,000
Common Stock Shares issued for Services (in Shares)	10,000
Stock-based compensation			905,182		905,182
Net Loss				(4,536,622)	(4,536,622)
Balance at Jun. 30, 2025	$ 29,665		$ 51,759,838	$ (46,845,856)	$ 4,943,647
Balance (in Shares) at Jun. 30, 2025	29,664,916				29,664,916

OS Therapies Inc 10-Q